Synthesis and evaluation of indomethacin prodrugs with a diester structure that are metabolically activated by human carboxylesterases

References

• Brzezinski MR, Spink BJ, Dean RA, Berkman CE, Cashman JR, Bosron WF. 1997. Human liver carboxylesterase hCE-1: binding specificity for cocaine, heroin, and their metabolites and analogs. Drug Metab Dispos. 25(9):1089–1096.
   PubMed Web of Science ®Google Scholar
• Fleming CD, Bencharit S, Edwards CC, Hyatt JL, Tsurkan L, Bai F, Fraga C, Morton CL, Howard-Williams EL, Potter PM, et al. 2005. Structural insights into drug processing by human carboxylesterase 1: tamoxifen, mevastatin, and inhibition by benzil. J Mol Biol. 352(1):165–177. doi: 10.1016/j.jmb.2005.07.016.
   PubMed Web of Science ®Google Scholar
• Fukami T, Kariya M, Kurokawa T, Iida A, Nakajima M. 2015. Comparison of substrate specificity among human arylacetamide deacetylase and carboxylesterases. Eur J Pharm Sci. 78:47–53. doi: 10.1016/j.ejps.2015.07.006.
   PubMed Web of Science ®Google Scholar
• Fukami T, Yokoi T. 2012. The emerging role of human esterases. Drug Metab Pharmacokinet. 27(5):466–477. doi: 10.2133/dmpk.dmpk-12-rv-042.
   PubMed Web of Science ®Google Scholar
• Higuchi R, Fukami T, Nakajima M, Yokoi T. 2013. Prilocaine- and lidocaine-induced methemoglobinemia is caused by human carboxylesterase-, CYP2E1-, and CYP3A4-mediated metabolic activation. Drug Metab Dispos. 41(6):1220–1230. doi: 10.1124/dmd.113.051714.
   PubMed Web of Science ®Google Scholar
• Hosokawa M. 2008. Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs. Molecules. 13(2):412–431. doi: 10.3390/molecules13020412.
   PubMed Web of Science ®Google Scholar
• Hosokawa M, Maki T, Satoh T. 1987. Multiplicity and regulation of hepatic microsomal carboxylesterases in rats. Mol Pharmacol. 31(6):579–584.
   PubMed Web of Science ®Google Scholar
• Hu Z-Y, Parker RB, Herring VL, Laizure SC. 2013. Conventional liquid chromatography/triple quadrupole mass spectrometry based metabolite identification and semi-quantitative estimation approach in the investigation of in vitro dabigatran etexilate metabolism. Anal Bioanal Chem. 405(5):1695–1704. doi: 10.1007/s00216-012-6576-4.
   PubMed Web of Science ®Google Scholar
• Imai T. 2006. Human carboxylesterase isozymes: catalytic properties and rational drug design. Drug Metab Pharmacokinet. 21(3):173–185. doi: 10.2133/dmpk.21.173.
   PubMed Web of Science ®Google Scholar
• Imai T, Taketani M, Shii M, Hosokawa M, Chiba K. 2006. Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine. Drug Metab Dispos. 34(10):1734–1741. doi: 10.1124/dmd.106.009381.
   PubMed Web of Science ®Google Scholar
• Jewell C, Ackermann C, Payne NA, Fate G, Voorman R, Williams FM. 2007. Specificity of procaine and ester hydrolysis by human, minipig, and rat skin and liver. Drug Metab Dispos. 35(11):2015–2022. doi: 10.1124/dmd.107.015727.
   PubMed Web of Science ®Google Scholar
• Kamendulis LM, Brzezinski MR, Pindel E. V, Bosron WF, Dean RA. 1996. Metabolism of cocaine and heroin is catalyzed by the same human liver carboxylesterases. J Pharmacol Exp Ther. 279(2):713–717.
   PubMed Web of Science ®Google Scholar
• Laizure SC, Parker RB, Herring VL, Hu Z-Y. 2014. Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis. Drug Metab Dispos. 42(2):201–206. doi: 10.1124/dmd.113.054353.
   PubMed Web of Science ®Google Scholar
• Mizoi K, Takahashi M, Haba M, Hosokawa M. 2016. Synthesis and evaluation of atorvastatin esters as prodrugs metabolically activated by human carboxylesterases. Bioorg Med Chem Lett. 26(3):921–923. doi: 10.1016/j.bmcl.2015.12.069.
   PubMed Web of Science ®Google Scholar
• Quinney SK, Sanghani SP, Davis WI, Hurley TD, Sun Z, Murry DJ, Bosron WF. 2005. Hydrolysis of capecitabine to 5’-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide. J Pharmacol Exp Ther. 313(3):1011–1016. doi: 10.1124/jpet.104.081265.
   PubMed Web of Science ®Google Scholar
• Satoh T, Hosokawa M. 1998. The mammalian carboxylesterases: from molecules to functions. Annu Rev Pharmacol Toxicol. 38(1):257–288. doi: 10.1146/annurev.pharmtox.38.1.257.
   PubMedGoogle Scholar
• Satoh T, Hosokawa M, Atsumi R, Suzuki W, Hakusui H, Nagai E. 1994. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1- piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol Pharm Bull. 17(5):662–664. doi: 10.1248/bpb.17.662.
   PubMed Web of Science ®Google Scholar
• Shi D, Yang J, Yang D, LeCluyse EL, Black C, You L, Akhlaghi F, Yan B. 2006. Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J Pharmacol Exp Ther. 319(3):1477–1484. doi: 10.1124/jpet.106.111807.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Hirota I, Nakano T, Kotani T, Takani D, Shiratori K, Choi Y, Haba M, Hosokawa M. 2021. Effects of steric hindrance and electron density of ester prodrugs on controlling the metabolic activation by human carboxylesterase. Drug Metab Pharmacokinet. 38:100391. doi: 10.1016/j.dmpk.2021.100391.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Ogawa T, Kashiwagi H, Fukushima F, Yoshitsugu M, Haba M, Hosokawa M. 2018. Chemical synthesis of an indomethacin ester prodrug and its metabolic activation by human carboxylesterase 1. Bioorg Med Chem Lett. 28(6):997–1000. doi: 10.1016/j.bmcl.2018.02.035.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Takani D, Haba M, Hosokawa M. 2020. Investigation of the chiral recognition ability of human carboxylesterase 1 using indomethacin esters. Chirality. 32(1):73–80. doi: 10.1002/chir.23141.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Uehara T, Nonaka M, Minagawa Y, Yamazaki R, Haba M, Hosokawa M. 2019. Synthesis and evaluation of haloperidol ester prodrugs metabolically activated by human carboxylesterase. Eur J Pharm Sci. 132:125–131. doi: 10.1016/j.ejps.2019.03.009.
   PubMed Web of Science ®Google Scholar
• Takai S, Matsuda A, Usami Y, Adachi T, Sugiyama T, Katagiri Y, Tatematsu M, Hirano K. 1997. Hydrolytic profile for ester- or amide-linkage by carboxylesterases pI 5.3 and 4.5 from human liver. Biol Pharm Bull. 20(8):869–873. doi: 10.1248/bpb.20.869.
   PubMed Web of Science ®Google Scholar
• Wadkins RM, Hyatt JL, Wei X, Yoon KJP, Wierdl M, Edwards CC, Morton CL, Obenauer JC, Damodaran K, Beroza P, et al. 2005. Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 48(8):2906–2915. doi: 10.1021/jm049011j.
   PubMed Web of Science ®Google Scholar
• Zhang J, Burnell JC, Dumaual N, Bosron WF. 1999. Binding and hydrolysis of meperidine by human liver carboxylesterase hCE-1. J Pharmacol Exp Ther. 290(1):314–318.
   PubMed Web of Science ®Google Scholar
• Zhu H-J, Wang X, Gawronski BE, Brinda BJ, Angiolillo DJ, Markowitz JS. 2013. Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. J Pharmacol Exp Ther. 344(3):665–672. doi: 10.1124/jpet.112.201640.
   PubMed Web of Science ®Google Scholar